866-997-4948(US-Canada Toll Free)

Alzheimers Disease - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Nov 2010

Category :

Therapeutic Area

No. of Pages : 62 Pages


GlobalData, the industry analysis specialist, has released its new report, Alzheimers Disease Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Alzheimers disease market. The report identifies the key trends shaping and driving the global Alzheimers disease market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Alzheimers disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData has estimated the global Alzheimers disease therapeutics market to be valued at $7.1 billion in 2009. It is expected to decline to $5.2 billion with a Compound Annual Growth Rate (CAGR) of (4%) by 2017. The market structure is projected to change in the near future following the patent expiry of the leading drugs in next 2-3 years. Aricept patent expires in November 2010, Namendas (Forest) patent is set to expire in April 2015. There is a high unmet need in the current Alzheimers disease market in terms of both safety and efficacy profile

Scope

The report provides information on the key drivers and challenges of the Alzheimers disease market. Its scope includes:
 
  • Annualized global Alzheimers disease market revenues data from 2001 to 2009, forecast for eight years to 2017. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as of cholinesterase inhibitors, N-methyl D-aspartate, serotonin receptor antagonists, immunotherapy, gamma secretase inhibitors and beta secretase inhibitors.
  • Analysis of the current and future competition in the global Alzheimers disease market. Key market players covered are Pfizer, AstraZeneca, Baxter Healthcare, Elan and Medivation.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Alzheimers disease therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Alzheimers disease market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Alzheimers disease market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Alzheimers disease market landscape? Identify, understand and capitalize.
Table Of Content

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Alzheimers Disease Therapeutics : Introduction 6
2.1 GlobalData Report Guidance 6

3 Alzheimers Disease Therapeutics: Market Characterization 7
3.1 Overview 7
3.2 Alzheimers Disease Therapeutics Market Size 7
3.3 Alzheimers Disease Therapeutics Market Forecast and CAGR 7
3.4 Drivers and Barriers for the Alzheimers Disease Therapeutics 9
3.4.1 Drivers for the Alzheimers Disease Therapeutics 9
3.4.2 Barriers for the Alzheimers Disease Therapeutics Market 9
3.5 Opportunity and Unmet Need 9
3.6 Key Takeaway 10

4 Alzheimers Disease Therapeutics: Competitive Assessment 11
4.1 Overview 11
4.2 Strategic Competitor Assessment 11
4.3 Product Profile for the Major Marketed Products in the Alzheimers Disease Therapeutics 12
4.3.1 Aricept (donepezil hydrochloride) 12
4.3.2 Exelon (rivastigmine titrate) 13
4.3.3 Namenda (memantine hydrochloride) 15
4.4 Other Marketed Products for Alzheimers Disease Therapeutics 16
4.4.1 Cognex 16
4.4.2 Razadyne (galantamine hydrobromide extended release capsules) 17
4.5 Key Takeaway 18

5 Alzheimers Disease Therapeutics: Pipeline Assessment 19
5.1 Overview 19
5.2 Strategic Pipeline Assessment 19
5.2.1 Technology Trends Analytical Framework 19
5.3 Alzheimers Disease Therapeutics-Promising Drugs Under Clinical Development 20
5.4 Molecular Profile for the Promising Drugs under Clinical Development 21
5.4.1 Bapineuzumab 21
5.4.2 Gammagard 22
5.4.3 Dimebon 23
5.4.4 Rember (Trx0014) (methylthionium chloride) 24
5.5 Alzheimers Disease Therapeutics Clinical Pipeline by Mechanism of Action 25
5.6 Alzheimers Disease Therapeutics Pipeline Pipeline by Clinical Phases of Development 26
5.6.1 Alzheimers Disease Therapeutics Regulatory and Phase III Clinical Pipeline 26
5.6.2 Alzheimers Disease Therapeutics Phase II Clinical Pipeline 27
5.6.3 Alzheimers Disease Therapeutics Phase I Clinical Pipeline 30
5.6.4 Alzheimers Disease Therapeutics Preclinical Pipeline 32
5.6.5 Alzheimers Disease Therapeutics Discovery Pipeline 35
5.7 Discontinued / Suspended Drugs for Alzheimers disease 37
5.8 Key Takeaway 40

6 Alzheimers Disease Therapeutics: Implications for the Future Market Competition 41

7 Alzheimers Disease Therapeutics: Future Players in the Market 43
7.1 Introduction 43
7.2 AstraZeneca 43
7.2.1 Overview 43
7.2.2 Central Nervous System Portfolio 44
7.2.3 Alzheimers disease Portfolio 45
7.3 Elan 46
7.3.1 Overview 46
7.3.2 CNS Portfolio 46
7.3.3 Alzheimers Disease Product Portfolio 47
7.4 Wyeth (Pfizer) 48
7.4.1 Overview 48
7.4.2 CNS Portfolio 49
7.4.3 Alzheimers Disease Product Portfolio 50
7.5 Medivation 52
7.5.1 Overview 52
7.5.2 CNS Portfolio 52
7.5.3 Alzheimers Disease Product Portfolio 53
7.6 Baxter Healthcare 53
7.6.1 Overview 53
7.6.2 CNS Portfolio 54
7.6.3 Alzheimers Disease Product Portfolio 54

8 Alzheimers Disease Therapeutics Market : Appendix 56
8.1 Market Definitions 56
8.2 Scope of Pipeline Research 56
8.3 Abbreviations 56
8.4 Research Methodology 58
8.4.1 Coverage 58
8.4.2 Secondary Research 58
8.4.3 Forecasting 58
8.4.4 Primary Research 61
8.4.5 Expert Panel validation 61
8.5 Contact Us 61
8.6 Disclaimer 61
8.7 Sources 62

List of Table


Table 1: Alzheimers Disease Therapeutics,Global ($bn)2001-2009 8
Table 2: Alzheimers Disease Therapeutics, Global, Market Forecast ($bn), 2009-2017 8
Table 3: Major marketed products comparison in Alzheimers Disease, 2010 18
Table 4: Alzheimers Disease Therapeutics Most Promising Drugs Under Clinical Development, 2010 20
Table 5: Alzheimers Disease Therapeutics Regulatory and Phase III Clinical Pipeline, 2010 26
Table 6: Alzheimers Disease Therapeutics Phase II Clinical Pipeline, 2010 27
Table 7: Alzheimers Disease Therapeutics Phase I Clinical Pipeline, 2010 30
Table 8: Alzheimers Disease Therapeutics Preclinical Pipeline, 2010 32
Table 9: Alzheimers Disease Therapeutics Discovery Pipeline, 2010 35
Table 10: List of Discontinued Drugs for Alzheimers Disease, 2010 37
Table 11: Alzheimers Disease Therapeutics List of Other Discontinued Drugs in Pipeline, 2010 40
Table 12: AstraZeneca CNS Marketed Products, 2010 44
Table 13: AstraZeneca CNS Pipeline Products, 2010 44
Table 14: Elan CNS Marketed Products, 2010 46
Table 15: Elan CNS Pipeline Products, 2010 46
Table 16: Wyeth (Pfizer) CNS Marketed Products, 2010 49
Table 17: Wyeth (Pfizer) CNS Pipeline Products, 2010 49
Table 18: Medivation CNS Pipeline Products, 2010 52
Table 19: Baxter Healthcare CNS Marketed Products, 2010 54
Table 20: Baxter Healthcare CNS Pipeline Products, 2010 54

List of Chart


Figure 1: Alzheimers Disease Therapeutics , Revenues, ($bn)2001-2009 7
Figure 2: Alzheimers Disease Therapeutics, Global, Market Forecast ($bn), 2009-2017 8
Figure 3: Opportunity and Unmet Need in the Alzheimers Disease Therapeutics, 2010 10
Figure 4: Srategic Competitor Assessment of the Major Marketed Products for Alzheimers Disease, 2010 11
Figure 5: Technology Trends Analytic Framework of Alzheimers Disease Therapeutics, 2010 19
Figure 6: Alzheimers Disease Therapeutics Clinical Pipeline by Mechanism of Action, 2010 25
Figure 7: Alzheimers Disease Therapeutics Pipeline by Phase of Clinical Development, 2010 26
Figure 8: Implications for Future Market Competition in the Alzheimers Disease Therapeutics Market,2010 41
Figure 9: Alzheimers Disease Therapeutics. Pipeline by Company, 2010 43
Figure 10: GlobalData Market Forecasting Model 60

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *